Indications |
Oral Severe anaerobic infections Adult: 500 mg 3 or 4 times daily. Child: ≥1 mth: 30-60 mg/kg daily in divided doses. Renal impairment: Severe impairment: Reduce to 25-30% of the usual dose. Hepatic impairment: Dose adjustment may be needed. Parenteral Severe anaerobic infections Adult: Dose can be administered by IM or IV inj. IM admin: 600 mg 1-2 times daily. IV admin: 0.6-1 g 2-3 times daily by slow IV infusion (over at least 1 hr), may increase up to a total of 8 g daily in severe infections. Child: >1 mth: 10-20 mg/kg daily in divided doses by IM inj or IV infusion. Renal impairment: Severe impairment: Reduce to 25-30% of the usual dose. Hepatic impairment: Dose adjustment may be needed. Subconjunctival Severe anaerobic infections Adult: Administer75 mg by subconjunctival inj to maintain sufficient MICs in the ocular fluid levels for at least 5 hr. Renal impairment: Severe impairment: Reduce to 25-30% of the usual dose. Hepatic impairment: Dose adjustment may be needed. Special Populations: Reduce dose by 20-30% in patients with severe renal impairment. Reconstitution: For IV admin: 1 g of lincomycin should be diluted in at least 100 ml of diluent. Incompatibility: Syringe incompatibility: Ampicillin. Admixture incompatibility: Phenytoin, kanamycin. |
Contraindications |
Hypersensitivity to lincomycin or clindamycin. |
Warnings / Precautions |
Elderly. Severe renal and hepatic impairment. Pregnancy and lactation. Monitor liver function and CBC on long-term treatment. History of GI disease e.g. colitis. |
Adverse Reactions |
Hypotension (IV); vertigo; dermatitis, erythema multiforme, rash, urticaria; colitis, diarrhoea, glossitis, nausea, vomiting, pruritus ani, stomatitis; vaginitis; agranulocytosis, aplastic anaemia, leukopenia, neutropenia, pancytopenia, thrombocytopenic purpura; jaundice, LFT abnormalities; tinnitus; azotaemia, proteinuria, oliguria; hypersensitivity reactions. Potentially Fatal: Anaphylaxis. IV: Syncope, CV collapse. |
Drug Interactions |
May potentiate effects of neuromuscular blocking agents. Reduced absorption with kaolin. May reduce effects of erythromycin. See Below for More lincomycin Drug Interactions |
Mechanism of Actions |
Lincomycin exerts bacteriostatic and bactericidal effects by binding to 50S ribosome subunit. This results in inhibition of protein synthesis, specifically peptide-bond formation, in susceptible organisms. Absorption: 20-30% is absorbed from the GI tract (oral); peak plasma concentrations after 2-4 hr. Food reduces rate and extent of absorption. Distribution: Widely into tissues, bone, body fluids; CSF (poor, except when meninges are inflamed); crosses the placenta and enters breast milk. Metabolism: Hepatic (partially inactivated). Excretion: Via bile, urine, faeces (as unchanged drug and metabolites); 5 hr (elimination half-life). |
Administration |
Should be taken on an empty stomach. (Take w/ full glass of water on an empty stomach 1 hr before or 2 hr after meals.) |
Storage Conditions |
Oral: Store at 20-25°C. Parenteral: Store at 20-25°C. Subconjunctival: Store at 20-25°C. |
ATC Classification |
J01FF02 - lincomycin ; Belongs to the class of lincosamides. Used in the systemic treatment of infections. |
Storage |
Oral: Store at 20-25°C. Parenteral: Store at 20-25°C. Subconjunctival: Store at 20-25°C. |
Available As |
|
Lincomycin
Post Review about Lincomycin Click here to cancel reply.
Lincomycin Containing Brands
Lincomycin is used in following diseases
Drug - Drug Interactions of Lincomycin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.